The lower risk of hypoglycaemia with sitagliptin relative to sulphonylureas overall is consistent with the glucose-dependent actions of DPP-4 inhibitors relative to the non-glucose-dependent mechanism of action of potassium channel-based insulin secretagogues, such as sulphonylureas (5,21). Here, INS is linked to Hypoglycemia.